{"entity":{"id":"nct07134218","kind":"trial","name":"Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer","aka":[],"tldr":"A phase 2/3 trial in colorectal cancer, run by Changhai Hospital, not yet recruiting.","summary":"Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer is a phase 2/3, randomised interventional study registered as NCT07134218 by Changhai Hospital, with a registry enrolment figure of 180 participants, started 2025-10 and due to reach its primary completion in 2027-10. Interventions recorded: serplulimab、bevacizumab; neoadjuvant chemoradiation therapy. Conditions listed: Rectal Cancer. Primary outcome: The rate of cCR. Colorectal eligibility wording from the registry: \"* Histologically confirmed rectal adenocarcinoma with immunohistochemistry results showing proficient mismatch repair (pMMR) or molecular testing results indicating microsatellite stability (MSS);\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07134218","url":"https://clinicaltrials.gov/study/NCT07134218"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","msi-high-colorectal"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07134218","phase":"2/3","setting":"A National Multicenter, Prospective, Randomized Controlled Study of Serplulimab Injection Combined With Bevacizumab to Improve the Complete Response Rate of Neoadjuvant Therapy for Locally Advanced Stage Intermediate and Low Rectal Cancer","sponsor":"Changhai Hospital","participation":[{"nct":"NCT07134218","source":"https://clinicaltrials.gov/study/NCT07134218","fetchedAt":"2026-10-07T16:55:28.490Z","studySha256":"6f601836e99da1dc795563c8eb0efb5bf4206435ffa7a190449a68f28a34c9a5","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2025-08-21","leadSponsor":"Changhai Hospital","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":180,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2025-10","startedType":"estimated","enrolled":180,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07134218/","neighbours":{"cancer":[{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}